Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), will present at the 43rd Annual J.P. Morgan Healthcare ...
Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback